^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Anal Carcinoma
    Drug:5-fluorouracil (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    5-FU with MMC combined with radiotherapy are generally recommended, rather than 5-FU and cisplatin, MMC and cisplatin, any single drug or any combination of three drugs.
    DOI:
    doi:10.1093/annonc/mdu159
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    JAMA
    Title:

    Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial

    Excerpt:
    ...Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal…The 5-year overall survival rate was 75% (95% CI, 67%-81%) in the mitomycin-based group and 70% (95% CI, 63%-76%) in the cisplatin-based group (P = .10).
    DOI:
    10.1001/jama.299.16.1914
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial

    Excerpt:
    Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus...with fluorouracil...3-year progression-free survival was 74% (95% CI 69-77; maintenance) versus 73% (95% CI 68-77; no maintenance; hazard ratio 0.95, 95% CI 0.75-1.21; p=0.70).
    DOI:
    10.1016/S1470-2045(13)70086-X